For instance, a clinical study [174] has shown that patients with MET-amplified esophagogastric cancer (EGC) develop resistance after about two months of MET inhibitor therapy, mainly due to the rapid growth of non-MET (EGFR or HER-2) amplified tumor cell subpopulations. This evidence concerns the gene EGFR and neoplasm.